Literature DB >> 33899121

Role of indoleamine 2,3-dioxygenase in ischemia-reperfusion injury of renal tubular epithelial cells.

Theodoros Eleftheriadis1, Georgios Pissas1, Spyridon Golfinopoulos1, Vassilios Liakopoulos1, Ioannis Stefanidis1.   

Abstract

The present study evaluated indoleamine 2,3‑dioxygenase 1 (IDO) kinetics and how it affects cell survival during the two distinct phases of ischemia‑reperfusion (I‑R) injury. Primary renal proximal tubular epithelial cells (RPTECs) were cultured under anoxia or reoxygenation with or without the IDO inhibitor 1‑DL‑methyltryptophan, the aryl‑hydrocarbon receptor (AhR) inhibitor CH223191 or the ferroptosis inhibitor α‑tocopherol. Using cell imaging, colorimetric assays, PCR and western blotting, it was demonstrated that IDO was upregulated and induced apoptosis during anoxia. The related molecular pathway entails tryptophan degradation, general control non‑derepressible‑2 kinase (GCN2K) activation, increased level of phosphorylated eukaryotic translation initiation factor 2α, activating transcription factor (ATF)4, ATF3, C/EBP homologous protein, phosphorylated p53, p53, Bax, death receptor‑5 and eventually activated cleaved caspase‑3. Reoxygenation also upregulated IDO, which, in this case, induced ferroptosis. The related molecular pathway encompasses kynurenine production, AhR activation, cytochrome p450 enzymes increase, reactive oxygen species generation and eventually ferroptosis. In conclusion, in RPTECs, both anoxia and reoxygenation upregulated IDO, which in turn induced GCN2K‑mediated apoptosis and AhR‑mediated ferroptosis. Since both phases of I‑R injury share IDO upregulation as a common point, its inhibition may prove a useful therapeutic strategy for preventing or attenuating I‑R injury.

Entities:  

Keywords:  3-dioxygenase; apoptosis; aryl-hydrocarbon receptor; ferroptosis; general control non-derepressible-2 kinase; indoleamine 2; ischemia-reperfusion

Year:  2021        PMID: 33899121     DOI: 10.3892/mmr.2021.12111

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  6 in total

Review 1.  Indoleamine 2,3 Dioxygenase 1-The Potential Link between the Innate Immunity and the Ischemia-Reperfusion-Induced Acute Kidney Injury?

Authors:  Anna Krupa; Mikolaj M Krupa; Krystyna Pawlak
Journal:  Int J Mol Sci       Date:  2022-05-31       Impact factor: 6.208

2.  The Role of Indoleamine 2,3-Dioxygenase in Renal Tubular Epithelial Cells Senescence under Anoxia or Reoxygenation.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Georgios Filippidis; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Biomolecules       Date:  2021-10-15

3.  Down-Regulation of Activating Transcription Factor 3 (ATF3) in Hepatoblastoma and Its Relationship with Ferroptosis.

Authors:  Jing-Xiao Li; Jin-Shu Pang; Bin-Tong Yin; Gang Chen; Jun-Hong Chen; Jia-Yuan Luo; Xia Yang; Li-Ting Qin; Jiang-Hui Zeng; Peng Chen; Jia-Bo Chen; Deng Tang
Journal:  Int J Gen Med       Date:  2021-12-06

4.  Biological Characteristics and Predictive Model of Biopsy-Proven Acute Rejection (BPAR) After Kidney Transplantation: Evidences of Multi-Omics Analysis.

Authors:  Qianguang Han; Xiang Zhang; Xiaohan Ren; Zhou Hang; Yu Yin; Zijie Wang; Hao Chen; Li Sun; Jun Tao; Zhijian Han; Ruoyun Tan; Min Gu; Xiaobing Ju
Journal:  Front Genet       Date:  2022-03-21       Impact factor: 4.772

5.  Puerarin Induces Molecular Details of Ferroptosis-Associated Anti-Inflammatory on RAW264.7 Macrophages.

Authors:  Jinzi Zeng; Ning Zhao; Jiajia Yang; Weiyang Kuang; Xuewei Xia; Xiaodan Chen; Zhiyuan Liu; Riming Huang
Journal:  Metabolites       Date:  2022-07-15

6.  CCN2 Aggravates the Immediate Oxidative Stress-DNA Damage Response following Renal Ischemia-Reperfusion Injury.

Authors:  Floris A Valentijn; Sebastiaan N Knoppert; Georgios Pissas; Raúl R Rodrigues-Diez; Laura Marquez-Exposito; Roel Broekhuizen; Michal Mokry; Lennart A Kester; Lucas L Falke; Roel Goldschmeding; Marta Ruiz-Ortega; Theodoros Eleftheriadis; Tri Q Nguyen
Journal:  Antioxidants (Basel)       Date:  2021-12-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.